# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...
Morgan Stanley analyst Terence Flynn maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target...
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(2.67) per share. This is a 1.91 percent decrease over losses of $(...
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 50 points on Tuesday.